Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) belong to the most common chronic inflammatory diseases (CIDs). While significant research efforts have led to improvements in treatment, ...
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, announced today the close of a $15 million Series A financing co-led by SPRIM ...